---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-050412"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2021-10-07T23:59:59+00:00"
generated_at: "2026-06-28T22:20:28.678076+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nkarta doses first patients in NKX019 Ph1; NKX101 initial data guided to 1H 2022

## Summary
- First patients dosed in Phase 1 trial of NKX019 for CD19+ B-cell malignancies (NHL, CLL, B-ALL).
- Initial data from NKX019 trial expected in 2022.
- Initial data from NKX101 Phase 1 in AML/MDS now expected in first half of 2022 (previously anticipated earlier).
- NKX101 cadence affected by haplomatched donor cell use, staggered enrollment, and COVID-19 disruptions.
- Protocol amended to allow off-the-shelf or haplomatched cells and to shorten patient stagger.

## SEC filing metadata
- accession: 0001564590-21-050412
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2021-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000156459021050412/0001564590-21-050412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000156459021050412/nktx-8k_20211007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-050412
- JSON: https://secwatch.observer/filing/0001564590-21-050412.json
- Plain text: https://secwatch.observer/filing/0001564590-21-050412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.